CareConekta: study protocol for a randomized controlled trial of a mobile health intervention to improve engagement in postpartum HIV care in South Africa.
Anti-HIV Agents
/ therapeutic use
Continuity of Patient Care
Female
HIV Infections
/ drug therapy
Humans
Infectious Disease Transmission, Vertical
/ prevention & control
Patient Acceptance of Health Care
Patient Preference
Postpartum Period
Pregnancy
Prospective Studies
Randomized Controlled Trials as Topic
Smartphone
South Africa
/ epidemiology
Telemedicine
Text Messaging
HIV/AIDS
Mobile health
Postpartum
Pregnancy
Retention
Smartphone
South Africa
Women
mHealth
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
12 Mar 2020
12 Mar 2020
Historique:
received:
04
02
2020
accepted:
19
02
2020
entrez:
14
3
2020
pubmed:
14
3
2020
medline:
29
12
2020
Statut:
epublish
Résumé
South Africa is home to the world's largest antiretroviral therapy program but sustaining engagement along the HIV care continuum has proven challenging in the country and throughout the wider region. Population mobility is common in South Africa, but there are important research gaps in describing this mobility and its impact on engagement in HIV care. Postpartum women and their infants in South Africa are known to be at high risk of dropping out of HIV care after delivery and are frequently mobile. In 2017, we developed a beta version of a smartphone application (app) - CareConekta - that detects a user's smartphone location to allow for prospective characterization of mobility. Now we will adapt and test CareConekta to conduct essential formative work on mobility and evaluate an intervention - the CareConekta app plus text notifications and phone calls and/or WhatsApp messages - to facilitate engagement in HIV care during times of mobility. During the 3-year project period, our first objective is to evaluate the feasibility, acceptability, and initial efficacy of using CareConekta as an intervention to improve engagement in HIV care. Our second objective is to characterize mobility among South African women during the peripartum period and its impact on engagement in HIV care. We will enroll 200 eligible pregnant women living with HIV and receiving care at the Gugulethu Midwife Obstetric Unit in Cape Town, South Africa. This work will provide critical information about mobility during the peripartum period and the impact on engagement in HIV care. Simultaneously, we will pilot test an intervention to improve engagement with rigorously assessed outcomes. If successful, CareConekta offers tremendous potential as a research and service tool that can be adapted and evaluated in multiple geographic regions, study contexts, and patient populations. ClinicalTrials.gov: NCT03836625. Registered on 8 February 2019.
Sections du résumé
BACKGROUND
BACKGROUND
South Africa is home to the world's largest antiretroviral therapy program but sustaining engagement along the HIV care continuum has proven challenging in the country and throughout the wider region. Population mobility is common in South Africa, but there are important research gaps in describing this mobility and its impact on engagement in HIV care. Postpartum women and their infants in South Africa are known to be at high risk of dropping out of HIV care after delivery and are frequently mobile.
METHODS
METHODS
In 2017, we developed a beta version of a smartphone application (app) - CareConekta - that detects a user's smartphone location to allow for prospective characterization of mobility. Now we will adapt and test CareConekta to conduct essential formative work on mobility and evaluate an intervention - the CareConekta app plus text notifications and phone calls and/or WhatsApp messages - to facilitate engagement in HIV care during times of mobility. During the 3-year project period, our first objective is to evaluate the feasibility, acceptability, and initial efficacy of using CareConekta as an intervention to improve engagement in HIV care. Our second objective is to characterize mobility among South African women during the peripartum period and its impact on engagement in HIV care. We will enroll 200 eligible pregnant women living with HIV and receiving care at the Gugulethu Midwife Obstetric Unit in Cape Town, South Africa.
DISCUSSION
CONCLUSIONS
This work will provide critical information about mobility during the peripartum period and the impact on engagement in HIV care. Simultaneously, we will pilot test an intervention to improve engagement with rigorously assessed outcomes. If successful, CareConekta offers tremendous potential as a research and service tool that can be adapted and evaluated in multiple geographic regions, study contexts, and patient populations.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov: NCT03836625. Registered on 8 February 2019.
Identifiants
pubmed: 32164771
doi: 10.1186/s13063-020-4190-x
pii: 10.1186/s13063-020-4190-x
pmc: PMC7068940
doi:
Substances chimiques
Anti-HIV Agents
0
Banques de données
ClinicalTrials.gov
['NCT03836625']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
258Subventions
Organisme : NIMH NIH HHS
ID : R34 MH118028
Pays : United States
Organisme : NIMH NIH HHS
ID : MH118028
Pays : United States
Références
J Midwifery Womens Health. 2003 Jul-Aug;48(4):268-72
pubmed: 12867911
J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):e102-9
pubmed: 26470033
J Acquir Immune Defic Syndr. 2015 Feb 26;69(2):e57-e65
pubmed: 25723138
J Acquir Immune Defic Syndr. 2010 May 1;54(1):35-41
pubmed: 20216425
J Health Soc Behav. 2000 Mar;41(1):50-67
pubmed: 10750322
AIDS Behav. 2017 Nov;21(11):3129-3140
pubmed: 28421356
AIDS Behav. 2016 Nov;20(11):2700-2708
pubmed: 27098408
AIDS Patient Care STDS. 2014 Jun;28(6):284-95
pubmed: 24839872
PLoS One. 2013 Oct 24;8(10):e78900
pubmed: 24205345
Matern Child Health J. 2015 Sep;19(9):2029-37
pubmed: 25656728
AIDS. 2013 Feb 20;27(4):645-50
pubmed: 23169326
AIDS. 2010 Sep 10;24(14):2263-70
pubmed: 20683318
PLoS One. 2016 Feb 26;11(2):e0147520
pubmed: 26918766
Clin Infect Dis. 2016 Aug 15;63(4):548-54
pubmed: 27208044
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Trop Med Int Health. 2013 Apr;18(4):451-60
pubmed: 23374278
Transgend Health. 2017 Jul 01;2(1):96-106
pubmed: 29082330
Arch Intern Med. 1998 Sep 14;158(16):1789-95
pubmed: 9738608
AIDS. 2008 Aug 20;22(13):1679-81
pubmed: 18670232
Psychosomatics. 2009 Nov-Dec;50(6):613-21
pubmed: 19996233
J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):383-389
pubmed: 28225717
Trop Med Int Health. 2010 Jun;15 Suppl 1:1-15
pubmed: 20586956
J Telemed Telecare. 2015 Mar;21(2):104-7
pubmed: 25586808
AIDS. 2011 Mar 27;25(6):825-34
pubmed: 21252632
HIV Med. 2017 Feb;18(2):80-88
pubmed: 27353189
S Afr Med J. 2009 May;99(5 Pt 2):375-82
pubmed: 19588801
AIDS Care. 2019 Jun;31(6):723-729
pubmed: 30596261
J Int AIDS Soc. 2018 Jul;21 Suppl 4:e25121
pubmed: 30027665
AIDS. 2015 Nov;29(17):2361-2
pubmed: 26258526
Environ Health Perspect. 2003 Jan;111(1):115-22
pubmed: 12515689
J Expo Anal Environ Epidemiol. 2001 May-Jun;11(3):207-15
pubmed: 11477518
PLoS One. 2012;7(9):e43832
pubmed: 22957034
Science. 2013 Feb 22;339(6122):961-5
pubmed: 23430655
PLoS One. 2010 Oct 08;5(10):e13198
pubmed: 20976289
S Afr Med J. 2011 Apr;101(4):253-7
pubmed: 21786730
Eur Addict Res. 2005;11(1):22-31
pubmed: 15608468
AIDS Care. 2016 Nov;28(11):1386-93
pubmed: 27145451
PLoS One. 2013;8(1):e54523
pubmed: 23336005
PLoS One. 2011;6(7):e21797
pubmed: 21818265
J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):e90-7
pubmed: 22421747
J Int AIDS Soc. 2014 Oct 08;17:19242
pubmed: 25301494
AIDS Care. 2012;24(6):680-6
pubmed: 22103696
Lancet. 2010 Nov 27;376(9755):1838-45
pubmed: 21071074
J Adolesc. 2016 Jul;50:65-8
pubmed: 27214713